Investor Relations

Company Description

News

Financial Reports

Financial Calendar

Presentations

The Share

New Issues

Corporate Governance

IR Contact

Dignitana delivers first DigniCap Delta in United States

Next generation scalp cooling device minimizes hair loss from chemotherapy

Files for download
Dignitana Release - wkr0006.pdf

Dignitana AB, industry leader in scalp cooling innovation, has installed the first DigniCap Delta® in the United States at the University of California, San Francisco (UCSF). The new device is the fourth generation of The DigniCap® Scalp Cooling System and received clearance from the United States Food and Drug Administration in June 2019. It is indicated to prevent chemotherapy-induced hair loss in patients with solid tumors. 

“The DigniCap pivotal trial paved the way for the introduction of effective, safe and convenient FDA-cleared scalp cooling in the United States,” says William Cronin, Chief Executive Officer of Dignitana AB. ”As that clinical trial was led by UCSF, it is both an honor and a privilege to introduce the new state-of-the-art DigniCap Delta device at UCSF as well.”

“Scalp cooling offers patients the opportunity to maintain privacy and self-esteem throughout chemotherapy, enhancing overall well-being and quality of life,” says Hope S. Rugo, MD, Professor of Medicine (Hematology/Oncology) and Director, Breast Oncology and Clinical Trials Education at UCSF who led the pivotal trial. “These innovations are critically important as we work to advance cancer care and treat the whole patient as well as the disease.”

Technical advancements in the new system include solid state cooling for precise temperature control and a streamlined design that is 54 percent smaller than the previous model. A new cap system gives patients a flexible Cooling Wrap and an adjustable Thermal Cap designed to optimize scalp cooling outcomes and minimize clinic storage needs. The intuitive user interface provides up to an 80 percent reduction in nursing time per patient infusion compared to the current model.

DigniCap Delta is now available to medical centers throughout the United States with the current scalp cooling system already available in in 30 U.S. states and 37 countries around the globe.

For More Information Contact

Anna Westesson, Anna Westesson PR & Consulting AB, anna@awprc.se  + 46 708-82 82 09

Caren Browning, King + Company,  caren.browning@kingcompr.com +1 212-561-7464

Melissa Bourestom, Dignitana AB,  melissa.bourestom@dignitana.com  +1 469-518-5031

About Dignitana AB (publ)

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001.  Dignitana AB is listed on Nasdaq First North Stockholm in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States.  Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Learn more at www.dignitana.se and www.dignicap.com.

Erik Penser Bank AB, Certified Adviser, +46 (0) 8 463 83 00 certifiedadviser@penser.se www.penser.se